Objective:To explore the effect of terbutaline sulfate combined with shunning on acute attack of asthma complicated with lobar pneumonia in children.Methods:One hundred and fifty children with acute attack of asthma a...Objective:To explore the effect of terbutaline sulfate combined with shunning on acute attack of asthma complicated with lobar pneumonia in children.Methods:One hundred and fifty children with acute attack of asthma and lobar pneumonia were randomly divided into routine group(seventy-five cases)and combined group(seventy-five cases).The routine group was given routine treatment.The study group was treated with routine therapy plus terbutaline sulfate plus shunning.The changes of pulmonary function and serum inflammatory factors before and after treatment,clinical effect and safety were compared between the two groups.Results:Respiratory time/inspiratory time(Ti/Te),peak time ratio(TPTEF/TE),peak volume ratio(VPEF/VE),tidal volume per kilogram(Vt/kg)were increased in both groups after treatment(P<0.05),which in the combined group were higher than the routine group after treatment(P<0.05).After treatment,serum levels of tumor necrosis factor-α(TNF-α),interleukin-6(IL-6)and interleukin-8(IL-8)in both groups decreased significantly(P<0.05),and those in the combined group were lower than those in the routine group(P<0.05).There was a significant difference in clinical effect distribution between the two groups(P<0.05).The total effective rate of the combined group was higher than that of the routine group(P<0.05).The incidence of adverse reactions in the combined group was slightly higher than that in the routine group(P>0.05).Conclusion:On the basis of routine treatment,terbutaline sulfate combined with shunning can significantly improve pulmonary function and serum inflammatory factors in children with acute attack of asthma and lobar pneumonia,with ideal effect and safe.展开更多
Objective:To investigate the clinical effect of interferon combined with inhalant therapy for acute attack of bronchial asthma.Methods: A total of 56 patients with acute attack of bronchial asthma who were treated in ...Objective:To investigate the clinical effect of interferon combined with inhalant therapy for acute attack of bronchial asthma.Methods: A total of 56 patients with acute attack of bronchial asthma who were treated in our hospital between January 2015 and January 2018 were selected as the research subjects, and the therapies were reviewed and used to divide the patients into the control group (n=30) who received conventional inhalant therapy and the interferon group (n=26) who received interferon combined with inhalant therapy. Control group received salbutamol aerosol inhalation, and interferon group received interferon combined with salbutamol aerosol inhalation. The differences in serum levels of inflammatory factors, airway remodeling indexes and immunoglobulins were compared between the two groups immediately after admission and after 48 h of treatment.Results:Immediately after admission, the differences in serum levels of inflammatory factors, airway remodeling indexes and immunoglobulins were not statistically significant between the two groups of patients. After 48 h of treatment, serum inflammatory factors IL-8, IL-17, IL-18, IL-25, IL-27 and IL-33 levels of interferon group were lower than those of control group;airway remodeling indexes VEGF, MMP-9 and TIMP1 levels were lower than those of control group;immunoglobulins IgA, IgG and IgM levels were higher than those of control group whereas IgE level was lower than that of control group.Conclusion:interferon combined with inhalant therapy can effectively reduce systemic inflammatory response, inhibit airway remodeling and optimize humoral immune function in patients with acute attack of bronchial asthma.展开更多
OBJECTIVE: To observe the effects of Suhuang Zhike Capsules on lung function and peripheral blood eosinophil count (EOS) and exhaled nitric oxide (eNO) in patients with acute asthma attack.METHODS: A total of 80 patie...OBJECTIVE: To observe the effects of Suhuang Zhike Capsules on lung function and peripheral blood eosinophil count (EOS) and exhaled nitric oxide (eNO) in patients with acute asthma attack.METHODS: A total of 80 patients with acute exacerbation of bronchial asthma admitted to Huai'an Cancer Hospital from January 2017 to January 2018 were randomly divided into an observation group and a control group,with 40 cases in each group.The control group was given conventional treatment with western medicine,and the observation group was given Suhuang Zhike Capsules on the basis of the treatment method of the control group.After 1 week of treatment,the improvement of individual symptoms (cough,wheezing,wheezing rale),lung function [1 second forced expiratory volume (FEV1),forced expiratory volume occupational capacity of vital capacity (FVC) in 1 second and peak expiratory flow (PEF)] and peripheral blood EOS and eNO levels and efficacy before and after the treatment were observed and assessed.RESULTS: The total effective rate of the observation group was 92.5%,which was significantly higher than the total effective rate of the control group (75.0%)(P < 0.05).The cough,wheezing and wheezing scores of the 2 groups were significantly decreased after treatment (P < 0.05).The scores of the above symptoms were significantly lower in the observation group than in the control group (P < 0.05).The FEV1,FVC and PEF were significantly increased after treatment (P < 0.05),and the above lung functions in the observation group were significantly higher than the control group (all P < 0.05).The EOS and eNO levels in the peripheral blood of the 2 groups were significantly decreased after treatment (P < 0.05),and the EOS and eNO levels in the peripheral blood in the observation group were significantly lower than those in the control group (P < 0.05).CONCLUSION: Suhuang Zhike Capsules can reduce the levels of EOS and eNO in peripheral blood of patients with acute asthma attack,improve the lung function of patients,relieve the clinical symptoms and improve the prognosis.展开更多
Objective:To explore the therapeutic effect of Dingchuan Decoction combined with omazumab on acute attack of bronchial asthma.Methods:From January 2020 to November 2021,90 patients with acute asthma were treated in ou...Objective:To explore the therapeutic effect of Dingchuan Decoction combined with omazumab on acute attack of bronchial asthma.Methods:From January 2020 to November 2021,90 patients with acute asthma were treated in our hospital,which belonged to heat asthma syndrome according to TCM syndrome differentiation in our hospital.They were divided into control group and observation group with 45 cases in each group.The control group was treated with omazumab,while the observation group was treated with omazumab combined with Dingchuan Decoction.The changes of lung function,exhaled nitric oxide(FeNO),blood gas indexes and hematological indexes were observed before and after treatment,and the adverse reactions and asthma recurrence within 3 months were observed.At the same time,animal experiments were carried out to verify the curative effect of Dingchuan.Results:After treatment,the total effective rate,FeNO,pulmonary function,partial pressure of blood oxygen(PaO_(2)),partial pressure of carbon dioxide(PaCO_(2)),interleukin-6(IL-6),interleukin-5(IL-5),immunoglobulin E(IgE)and asthma recurrence in 3 months in the observation group were better than those in the control group;There was no significant difference in pulse oxygen saturation(SaO_(2))and the incidence of adverse reactions between the two groups.Animal experiments show that Dingchuan Decoction can effectively improve lung inflammation.Conclusion:The combination of Dingchua Decoction and omazumab has a good curative effect in the treatment of acute attack of bronchial asthma,which can effectively improve the lung function and blood gas index of patients,reduce the levels of inflammatory factors and IgE,and has no obvious increase in adverse reactions,and effectively control the recurrence of asthma within 3 months.It can be used as an auxiliary maintenance treatment for patients with mild and moderate acute attack and clinical remission of asthma,thus reducing the utilization rate of hormones and having high application value.展开更多
基金General project of natural science foundation of Jiangsu province(No.BK20151112)Medical innovation team of Jiangsu province(No.CXTDB2017016).
文摘Objective:To explore the effect of terbutaline sulfate combined with shunning on acute attack of asthma complicated with lobar pneumonia in children.Methods:One hundred and fifty children with acute attack of asthma and lobar pneumonia were randomly divided into routine group(seventy-five cases)and combined group(seventy-five cases).The routine group was given routine treatment.The study group was treated with routine therapy plus terbutaline sulfate plus shunning.The changes of pulmonary function and serum inflammatory factors before and after treatment,clinical effect and safety were compared between the two groups.Results:Respiratory time/inspiratory time(Ti/Te),peak time ratio(TPTEF/TE),peak volume ratio(VPEF/VE),tidal volume per kilogram(Vt/kg)were increased in both groups after treatment(P<0.05),which in the combined group were higher than the routine group after treatment(P<0.05).After treatment,serum levels of tumor necrosis factor-α(TNF-α),interleukin-6(IL-6)and interleukin-8(IL-8)in both groups decreased significantly(P<0.05),and those in the combined group were lower than those in the routine group(P<0.05).There was a significant difference in clinical effect distribution between the two groups(P<0.05).The total effective rate of the combined group was higher than that of the routine group(P<0.05).The incidence of adverse reactions in the combined group was slightly higher than that in the routine group(P>0.05).Conclusion:On the basis of routine treatment,terbutaline sulfate combined with shunning can significantly improve pulmonary function and serum inflammatory factors in children with acute attack of asthma and lobar pneumonia,with ideal effect and safe.
文摘Objective:To investigate the clinical effect of interferon combined with inhalant therapy for acute attack of bronchial asthma.Methods: A total of 56 patients with acute attack of bronchial asthma who were treated in our hospital between January 2015 and January 2018 were selected as the research subjects, and the therapies were reviewed and used to divide the patients into the control group (n=30) who received conventional inhalant therapy and the interferon group (n=26) who received interferon combined with inhalant therapy. Control group received salbutamol aerosol inhalation, and interferon group received interferon combined with salbutamol aerosol inhalation. The differences in serum levels of inflammatory factors, airway remodeling indexes and immunoglobulins were compared between the two groups immediately after admission and after 48 h of treatment.Results:Immediately after admission, the differences in serum levels of inflammatory factors, airway remodeling indexes and immunoglobulins were not statistically significant between the two groups of patients. After 48 h of treatment, serum inflammatory factors IL-8, IL-17, IL-18, IL-25, IL-27 and IL-33 levels of interferon group were lower than those of control group;airway remodeling indexes VEGF, MMP-9 and TIMP1 levels were lower than those of control group;immunoglobulins IgA, IgG and IgM levels were higher than those of control group whereas IgE level was lower than that of control group.Conclusion:interferon combined with inhalant therapy can effectively reduce systemic inflammatory response, inhibit airway remodeling and optimize humoral immune function in patients with acute attack of bronchial asthma.
文摘OBJECTIVE: To observe the effects of Suhuang Zhike Capsules on lung function and peripheral blood eosinophil count (EOS) and exhaled nitric oxide (eNO) in patients with acute asthma attack.METHODS: A total of 80 patients with acute exacerbation of bronchial asthma admitted to Huai'an Cancer Hospital from January 2017 to January 2018 were randomly divided into an observation group and a control group,with 40 cases in each group.The control group was given conventional treatment with western medicine,and the observation group was given Suhuang Zhike Capsules on the basis of the treatment method of the control group.After 1 week of treatment,the improvement of individual symptoms (cough,wheezing,wheezing rale),lung function [1 second forced expiratory volume (FEV1),forced expiratory volume occupational capacity of vital capacity (FVC) in 1 second and peak expiratory flow (PEF)] and peripheral blood EOS and eNO levels and efficacy before and after the treatment were observed and assessed.RESULTS: The total effective rate of the observation group was 92.5%,which was significantly higher than the total effective rate of the control group (75.0%)(P < 0.05).The cough,wheezing and wheezing scores of the 2 groups were significantly decreased after treatment (P < 0.05).The scores of the above symptoms were significantly lower in the observation group than in the control group (P < 0.05).The FEV1,FVC and PEF were significantly increased after treatment (P < 0.05),and the above lung functions in the observation group were significantly higher than the control group (all P < 0.05).The EOS and eNO levels in the peripheral blood of the 2 groups were significantly decreased after treatment (P < 0.05),and the EOS and eNO levels in the peripheral blood in the observation group were significantly lower than those in the control group (P < 0.05).CONCLUSION: Suhuang Zhike Capsules can reduce the levels of EOS and eNO in peripheral blood of patients with acute asthma attack,improve the lung function of patients,relieve the clinical symptoms and improve the prognosis.
文摘Objective:To explore the therapeutic effect of Dingchuan Decoction combined with omazumab on acute attack of bronchial asthma.Methods:From January 2020 to November 2021,90 patients with acute asthma were treated in our hospital,which belonged to heat asthma syndrome according to TCM syndrome differentiation in our hospital.They were divided into control group and observation group with 45 cases in each group.The control group was treated with omazumab,while the observation group was treated with omazumab combined with Dingchuan Decoction.The changes of lung function,exhaled nitric oxide(FeNO),blood gas indexes and hematological indexes were observed before and after treatment,and the adverse reactions and asthma recurrence within 3 months were observed.At the same time,animal experiments were carried out to verify the curative effect of Dingchuan.Results:After treatment,the total effective rate,FeNO,pulmonary function,partial pressure of blood oxygen(PaO_(2)),partial pressure of carbon dioxide(PaCO_(2)),interleukin-6(IL-6),interleukin-5(IL-5),immunoglobulin E(IgE)and asthma recurrence in 3 months in the observation group were better than those in the control group;There was no significant difference in pulse oxygen saturation(SaO_(2))and the incidence of adverse reactions between the two groups.Animal experiments show that Dingchuan Decoction can effectively improve lung inflammation.Conclusion:The combination of Dingchua Decoction and omazumab has a good curative effect in the treatment of acute attack of bronchial asthma,which can effectively improve the lung function and blood gas index of patients,reduce the levels of inflammatory factors and IgE,and has no obvious increase in adverse reactions,and effectively control the recurrence of asthma within 3 months.It can be used as an auxiliary maintenance treatment for patients with mild and moderate acute attack and clinical remission of asthma,thus reducing the utilization rate of hormones and having high application value.
